Black Diamond Therapeutics (BDTX) Free Cash Flow (2019 - 2021)
Historic Free Cash Flow for Black Diamond Therapeutics (BDTX) over the last 3 years, with Q4 2021 value amounting to -$24.4 million.
- Black Diamond Therapeutics' Free Cash Flow fell 5349.12% to -$24.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$102.9 million, marking a year-over-year decrease of 9671.44%. This contributed to the annual value of -$62.3 million for FY2024, which is 666.22% up from last year.
- As of Q4 2021, Black Diamond Therapeutics' Free Cash Flow stood at -$24.4 million, which was down 5349.12% from -$27.7 million recorded in Q3 2021.
- Over the past 5 years, Black Diamond Therapeutics' Free Cash Flow peaked at -$5.0 million during Q2 2019, and registered a low of -$27.7 million during Q3 2021.
- Its 3-year average for Free Cash Flow is -$15.0 million, with a median of -$12.5 million in 2020.
- Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 17194.88% in 2020, then crashed by 5349.12% in 2021.
- Black Diamond Therapeutics' Free Cash Flow (Quarter) stood at -$7.5 million in 2019, then crashed by 112.11% to -$15.9 million in 2020, then crashed by 53.49% to -$24.4 million in 2021.
- Its Free Cash Flow was -$24.4 million in Q4 2021, compared to -$27.7 million in Q3 2021 and -$26.0 million in Q2 2021.